CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials

Katherine J. Wert, Susanne F. Koch, Gabriel Velez, Chun Wei Hsu, Mary Ann Mahajan, Alexander G. Bassuk, Stephen H. Tsang, Vinit B. Mahajan

Research output: Contribution to journalArticle

Abstract

Small molecule pharmacological inhibition of dominant human genetic disease is a feasible treatment that does not rely on the development of individual, patient-specific gene therapy vectors. However, the consequences of protein inhibition as a clinical therapeutic are not well-studied. In advance of human therapeutic trials for CAPN5 vitreoretinopathy, genetic inactivation can be used to infer the effect of protein inhibition in vivo. We created a photoreceptor-specific knockout (KO) mouse for Capn5 and compared the retinal phenotype to both wild-type and an existing Capn5 KO mouse model. In humans, CAPN5 loss-of-function (LOF) gene variants were ascertained in large exome databases from 60,706 unrelated subjects without severe disease phenotypes. Ocular examination of the retina of Capn5 KO mice by histology and electroretinography showed no significant abnormalities. In humans, there were 22 LOF CAPN5 variants located throughout the gene and in all major protein domains. Structural modeling of coding variants showed these LOF variants were nearby known disease-causing variants within the proteolytic core and in regions of high homology between human CAPN5 and 150 homologs, yet the LOF of CAPN5 was tolerated as opposed to gain-of-function disease-causing variants. These results indicate that localized inhibition of CAPN5 is a viable strategy for hyperactivating disease alleles.

Original languageEnglish (US)
Pages (from-to)2377-2392
Number of pages16
JournalHuman Mutation
Volume40
Issue number12
DOIs
StatePublished - Dec 1 2019
Externally publishedYes

Fingerprint

Knockout Mice
Phenotype
Exome
Electroretinography
Inborn Genetic Diseases
Medical Genetics
Therapeutics
Genetic Therapy
Genes
Retina
Histology
Proteins
Alleles
Databases
Pharmacology

Keywords

  • ADNIV
  • calpain-5
  • gene therapy
  • human gene variants
  • loss-of-function
  • retina

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Wert, K. J., Koch, S. F., Velez, G., Hsu, C. W., Mahajan, M. A., Bassuk, A. G., ... Mahajan, V. B. (2019). CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials. Human Mutation, 40(12), 2377-2392. https://doi.org/10.1002/humu.23894

CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials. / Wert, Katherine J.; Koch, Susanne F.; Velez, Gabriel; Hsu, Chun Wei; Mahajan, Mary Ann; Bassuk, Alexander G.; Tsang, Stephen H.; Mahajan, Vinit B.

In: Human Mutation, Vol. 40, No. 12, 01.12.2019, p. 2377-2392.

Research output: Contribution to journalArticle

Wert, KJ, Koch, SF, Velez, G, Hsu, CW, Mahajan, MA, Bassuk, AG, Tsang, SH & Mahajan, VB 2019, 'CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials', Human Mutation, vol. 40, no. 12, pp. 2377-2392. https://doi.org/10.1002/humu.23894
Wert KJ, Koch SF, Velez G, Hsu CW, Mahajan MA, Bassuk AG et al. CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials. Human Mutation. 2019 Dec 1;40(12):2377-2392. https://doi.org/10.1002/humu.23894
Wert, Katherine J. ; Koch, Susanne F. ; Velez, Gabriel ; Hsu, Chun Wei ; Mahajan, Mary Ann ; Bassuk, Alexander G. ; Tsang, Stephen H. ; Mahajan, Vinit B. / CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials. In: Human Mutation. 2019 ; Vol. 40, No. 12. pp. 2377-2392.
@article{67310c54d8854d6bb59e2c631c77d7a9,
title = "CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials",
abstract = "Small molecule pharmacological inhibition of dominant human genetic disease is a feasible treatment that does not rely on the development of individual, patient-specific gene therapy vectors. However, the consequences of protein inhibition as a clinical therapeutic are not well-studied. In advance of human therapeutic trials for CAPN5 vitreoretinopathy, genetic inactivation can be used to infer the effect of protein inhibition in vivo. We created a photoreceptor-specific knockout (KO) mouse for Capn5 and compared the retinal phenotype to both wild-type and an existing Capn5 KO mouse model. In humans, CAPN5 loss-of-function (LOF) gene variants were ascertained in large exome databases from 60,706 unrelated subjects without severe disease phenotypes. Ocular examination of the retina of Capn5 KO mice by histology and electroretinography showed no significant abnormalities. In humans, there were 22 LOF CAPN5 variants located throughout the gene and in all major protein domains. Structural modeling of coding variants showed these LOF variants were nearby known disease-causing variants within the proteolytic core and in regions of high homology between human CAPN5 and 150 homologs, yet the LOF of CAPN5 was tolerated as opposed to gain-of-function disease-causing variants. These results indicate that localized inhibition of CAPN5 is a viable strategy for hyperactivating disease alleles.",
keywords = "ADNIV, calpain-5, gene therapy, human gene variants, loss-of-function, retina",
author = "Wert, {Katherine J.} and Koch, {Susanne F.} and Gabriel Velez and Hsu, {Chun Wei} and Mahajan, {Mary Ann} and Bassuk, {Alexander G.} and Tsang, {Stephen H.} and Mahajan, {Vinit B.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1002/humu.23894",
language = "English (US)",
volume = "40",
pages = "2377--2392",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials

AU - Wert, Katherine J.

AU - Koch, Susanne F.

AU - Velez, Gabriel

AU - Hsu, Chun Wei

AU - Mahajan, Mary Ann

AU - Bassuk, Alexander G.

AU - Tsang, Stephen H.

AU - Mahajan, Vinit B.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Small molecule pharmacological inhibition of dominant human genetic disease is a feasible treatment that does not rely on the development of individual, patient-specific gene therapy vectors. However, the consequences of protein inhibition as a clinical therapeutic are not well-studied. In advance of human therapeutic trials for CAPN5 vitreoretinopathy, genetic inactivation can be used to infer the effect of protein inhibition in vivo. We created a photoreceptor-specific knockout (KO) mouse for Capn5 and compared the retinal phenotype to both wild-type and an existing Capn5 KO mouse model. In humans, CAPN5 loss-of-function (LOF) gene variants were ascertained in large exome databases from 60,706 unrelated subjects without severe disease phenotypes. Ocular examination of the retina of Capn5 KO mice by histology and electroretinography showed no significant abnormalities. In humans, there were 22 LOF CAPN5 variants located throughout the gene and in all major protein domains. Structural modeling of coding variants showed these LOF variants were nearby known disease-causing variants within the proteolytic core and in regions of high homology between human CAPN5 and 150 homologs, yet the LOF of CAPN5 was tolerated as opposed to gain-of-function disease-causing variants. These results indicate that localized inhibition of CAPN5 is a viable strategy for hyperactivating disease alleles.

AB - Small molecule pharmacological inhibition of dominant human genetic disease is a feasible treatment that does not rely on the development of individual, patient-specific gene therapy vectors. However, the consequences of protein inhibition as a clinical therapeutic are not well-studied. In advance of human therapeutic trials for CAPN5 vitreoretinopathy, genetic inactivation can be used to infer the effect of protein inhibition in vivo. We created a photoreceptor-specific knockout (KO) mouse for Capn5 and compared the retinal phenotype to both wild-type and an existing Capn5 KO mouse model. In humans, CAPN5 loss-of-function (LOF) gene variants were ascertained in large exome databases from 60,706 unrelated subjects without severe disease phenotypes. Ocular examination of the retina of Capn5 KO mice by histology and electroretinography showed no significant abnormalities. In humans, there were 22 LOF CAPN5 variants located throughout the gene and in all major protein domains. Structural modeling of coding variants showed these LOF variants were nearby known disease-causing variants within the proteolytic core and in regions of high homology between human CAPN5 and 150 homologs, yet the LOF of CAPN5 was tolerated as opposed to gain-of-function disease-causing variants. These results indicate that localized inhibition of CAPN5 is a viable strategy for hyperactivating disease alleles.

KW - ADNIV

KW - calpain-5

KW - gene therapy

KW - human gene variants

KW - loss-of-function

KW - retina

UR - http://www.scopus.com/inward/record.url?scp=85071127925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071127925&partnerID=8YFLogxK

U2 - 10.1002/humu.23894

DO - 10.1002/humu.23894

M3 - Article

C2 - 31403230

AN - SCOPUS:85071127925

VL - 40

SP - 2377

EP - 2392

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 12

ER -